OSI: Tarceva Approved as Maintenance Treatment for Lung Cancer
Prohost Biotech
•
Tue, Jul 14, 2009
Quote & Headlines
StockTalk
FOCUS
|
PRO
|
RELATED
|
TRANSCRIPTS
|
NEWS & PR
-
-
OSI Pharma Divvies Up Recent $175MM Private PlacementAdam Rubenstein • Thu, Jan 17, 2008
To learn more about Seeking Alpha Pro, click here.
-
Companies Give Back Q1 Gains - What Could Spark Q3?The Burrill Report • Mon, Jul 19, 2010
-
Merger Arbitrage Mondays: May 24, 2010Asif Suria • Tue, May 25, 2010
-
Astellas Buyout of OSI Pharmaceuticals Gets More LikelyDerek Lowe • Wed, May 19, 2010
-
Astellas to Acquire OSI Pharma for Around $4BZacks Investment Research • Tue, May 18, 2010
-
Astellas Finally Joins Peers With Major Overseas AcquisitionEP Vantage • Tue, May 18, 2010
-
Best Performing Russell 3000 Stocks Year to DateBespoke Investment Group • Thu, Apr 22, 2010
-
Astellas Remains Unchallenged in Bid for OSI PharmaThe Burrill Report • Mon, Apr 19, 2010
-
Monday Options Brief: OSIP, BONT, UA & XRTInteractive Brokers • Mon, Apr 12, 2010
-
OSI Pharma Balks at Astellas' AdvancesThe Burrill Report • Mon, Mar 22, 2010
-
OSI Pharmaceuticals, Inc. Q3 2009 Earnings Call TranscriptWed, Oct 21, 2009
-
OSI Pharmaceuticals, Inc. Q2 2009 Earnings Call TranscriptThu, Jul 23, 2009
-
OSI Pharmaceuticals, Inc. Q1 2009 Earnings Call TranscriptWed, Apr 29, 2009
-
OSI Pharmaceuticals, Inc. Q4 2008 Earnings Call TranscriptFri, Feb 20, 2009
-
OSI Pharmaceuticals, Inc. Q3 2008 Earnings Call TranscriptThu, Oct 23, 2008
-
OSI Pharmaceuticals Inc. Q2 2008 Earnings Call TranscriptWed, Jul 23, 2008
-
OSI Pharmaceuticals Inc. Q1 2008 Earnings Call TranscriptTue, May 6, 2008
-
OSI Pharmaceuticals Inc. Q4 2007 Earnings Call TranscriptThu, Feb 21, 2008
-
at MarketWatch.com (Jun 4, 2010)
-
at MarketWatch.com (May 18, 2010)
-
at CNBC.com (May 17, 2010)
-
at CNBC.com (May 17, 2010)
-
at CNBC.com (May 17, 2010)
-
at MarketWatch.com (May 17, 2010)
-
at MarketWatch.com (May 16, 2010)
-
at MarketWatch.com (May 14, 2010)
Company Description
We are a biotechnology company committed to building a scientifically strong and financially successful top tier biopharmaceutical organization that discovers, develops and commercializes innovative molecular targeted therapies, or MTTs, addressing major unmet medical needs in oncology, diabetes... More
Country: United States
